Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.47 |
| ▸ | CTSD | P07339 | 2/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | BMP1 | P13497 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28605707 | 1.00 | BACE1 (0.47) | BACE1CTSDBACE2ENPEPDPP4 | |
| SCHEMBL29630636 | 0.92 | BMP1 (0.46) | BACE1CTSDBACE2DPP4DPP8 | |
| SCHEMBL30421249 | 0.92 | BACE1 (0.53) | BACE1CTSDBACE2ENPEPDPP4 | |
| SCHEMBL18797432 | 0.92 | DPP4 (0.54) | BACE1CTSDBACE2ENPEPDPP4 | |
| SCHEMBL30997439 | 0.92 | DPP4 (0.54) | BACE1CTSDBACE2ENPEPDPP4 | |
| SCHEMBL6386178 | 0.92 | DPP4 (0.54) | BACE1CTSDBACE2ENPEPDPP4 | |
| SCHEMBL31181173 | 0.91 | ENPEP (0.44) | BACE1CTSDBACE2ENPEP | |
| SCHEMBL31089740 | 0.91 | ENPEP (0.55) | BACE1CTSDBACE2ENPEP | |
| SCHEMBL5194261 | 0.91 | ENPEP (0.55) | BACE1CTSDBACE2ENPEP | |
| SCHEMBL31423329 | 0.90 | ENPEP (0.46) | BACE1CTSDBACE2ENPEPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3806661-B1 | USE OF ANTAGONISTS OF T2R54 | FIRMENICH INCORPORATED (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4566459-A2 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | Firmenich Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240114942-A1 | Antagonists of T2R54 and Compositions and Uses Thereof | FIRMENICH INCORPORATED (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2024-01-16 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220330591-A1 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | FIRMENICH INCORPORATED (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | SENOMYX INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | SENOMYX INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-8609362-B2 | G-proteins | GIVAUDAN SA (CH) | 2013-12-17 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2629609-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110177545-A1 | G-PROTEINS | GIVAUDAN SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-7919236-B2 | G-proteins | GIVAUDAN SA (CH) | 2011-04-05 | — | — | US | disclosed |
| EP-1581555-B1 | CHIMERIC ALPHA Q-GUSTDUCIN G-PROTEINS | GIVAUDAN SA (CH) | 2008-04-30 | — | — | EP | disclosed |
| US-20060275765-A1 | G-proteins | GIVAUDAN SA (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | BACE1 4303/4885CTSD 3587/4885BACE2 4160/4885 |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | BACE1 4451/4885CTSD 3915/4885BACE2 3234/4885 |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | TAS2R5, TAS1R1, TAS2R1 | BACE1 720/4885CTSD 4211/4885BACE2 1950/4885 |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | BACE1 4451/4885CTSD 3915/4885BACE2 3234/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | BACE1 4303/4885CTSD 3587/4885BACE2 4160/4885 |
| US-20240114942-A1 | Antagonists of T2R54 and Compositions and Uses Thereof | TAS2R50, TAS2R30, TAS2R60 | BACE1 4451/4885CTSD 3915/4885BACE2 3234/4885 |
| US-20220330591-A1 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | TAS2R50, TAS2R30, TAS2R60 | BACE1 4451/4885CTSD 3915/4885BACE2 3234/4885 |
| US-20170087199-A1 | COMPOSITIONS FOR DELIVERING A COOLING SENSATION | TRPA1, PDE6G, PDE6D | BACE1 1784/4885CTSD 2136/4885BACE2 3218/4885 |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | BACE1 2690/4885CTSD 3706/4885BACE2 2980/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | BACE1 4303/4885CTSD 3587/4885BACE2 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.